359 related articles for article (PubMed ID: 16832678)
1. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
2. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
3. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
4. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
5. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
Lee LS; Bertino JS; Nafziger AN
J Clin Pharmacol; 2006 Feb; 46(2):229-34. PubMed ID: 16432275
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
7. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
8. Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans.
Hu ZY; Zhao YS; Wu D; Cheng ZN
Clin Chim Acta; 2009 Oct; 408(1-2):92-7. PubMed ID: 19654004
[TBL] [Abstract][Full Text] [Related]
9. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
[TBL] [Abstract][Full Text] [Related]
11. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
12. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
13. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.
Lin YS; Lockwood GF; Graham MA; Brian WR; Loi CM; Dobrinska MR; Shen DD; Watkins PB; Wilkinson GR; Kharasch ED; Thummel KE
Pharmacogenetics; 2001 Dec; 11(9):781-91. PubMed ID: 11740342
[TBL] [Abstract][Full Text] [Related]
14. Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats.
Bittner B; González RC; Isel H; Flament C
Eur J Pharm Biopharm; 2003 Jul; 56(1):143-6. PubMed ID: 12837492
[TBL] [Abstract][Full Text] [Related]
15. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
Yang J; Atkins WM; Isoherranen N; Paine MF; Thummel KE
Clin Pharmacol Ther; 2012 Mar; 91(3):442-9. PubMed ID: 22048224
[TBL] [Abstract][Full Text] [Related]
16. Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers.
Yan D; Yang Y; Uchida S; Misaka S; Luo J; Takeuchi K; Inui N; Yamada S; Ohashi K; Watanabe H
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):629-36. PubMed ID: 18157519
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
Kharasch ED; Francis A; London A; Frey K; Kim T; Blood J
Clin Pharmacol Ther; 2011 Jul; 90(1):100-8. PubMed ID: 21562488
[TBL] [Abstract][Full Text] [Related]
19. [Optimization of midazolam dosage and pharmacokinetics of CYP3A probe substrate in rats].
Qin XL; Duan WH; Xue XP; Chen X; Huang M; Bi HC
Yao Xue Xue Bao; 2016 May; 51(5):834-8. PubMed ID: 29878735
[TBL] [Abstract][Full Text] [Related]
20. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
